TG Therapeutics, Inc.
TGTX
$41.97
+16.26%
TG Therapeutics, Inc. is a commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases, primarily operating in the multiple sclerosis and oncology markets. The company has established itself as a commercial-stage player with its lead asset, BRIUMVI (ublituximab-xiiy), an FDA-approved therapy for relapsing forms of multiple sclerosis (RMS), positioning it as a challenger in the competitive MS treatment landscape. The current investor narrative is centered on the successful commercial launch and revenue ramp of BRIUMVI, with recent quarterly results showing significant year-over-year growth, alongside the ongoing development of its pipeline assets, which fuels the debate around its long-term growth potential and market share capture against established competitors.…
TGTX
TG Therapeutics, Inc.
$41.97
Investment Opinion: Should I buy TGTX Today?
Rating: Buy. The core thesis is that TGTX is a commercially de-risked growth story trading at a deeply discounted valuation, with recent quarterly execution strongly supporting the bull case.
Supporting evidence includes a trailing PE of 9.62, which is a fraction of typical biotech valuations, signaling undervaluation. Revenue growth of 78% YoY is exceptional and accelerating sequentially (+19% QoQ). The company has achieved profitability with a 26.22% operating margin and maintains a robust balance sheet (D/E of 0.40). While a consensus price target is absent, the implied growth in the forward PE (14.35 vs. trailing 9.62) suggests analysts expect significant earnings expansion.
The two biggest risks are a slowdown in BRIUMVI revenue growth below 15% sequentially and a resurgence of negative free cash flow. This Buy rating would downgrade to Hold if quarterly revenue growth decelerates to the low-teens sequentially or if the PE multiple expands above 25x without corresponding earnings growth. It would downgrade to Sell on a quarterly revenue decline. The stock is undervalued relative to its own profitable growth trajectory and the biotech sector, though fairly valued when factoring in its single-product risk and high volatility.
Sign up to view all
TGTX 12-Month Price Forecast
The fundamental picture of accelerating revenue and profitability starkly contrasts with a depressed valuation and negative market sentiment, creating a compelling asymmetry. The high beta is a double-edged sword but could work in favor of bulls if positive catalysts emerge. The stance is bullish but with medium confidence due to the binary nature of the single-asset reliance and the stock's proven volatility. The stance would upgrade to high-confidence bullish on two consecutive quarters of sequential revenue growth above 10% and sustained positive operating cash flow. It would downgrade to neutral on any quarter of sequential revenue decline.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TG Therapeutics, Inc.'s 12-month outlook, with a consensus price target around $54.56 and implied upside of +30.0% versus the current price.
Average Target
$54.56
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$34 - $55
Analyst target range
Analyst coverage for TGTX is limited, with only 3 analysts providing estimates, which is typical for a commercial-stage small-to-mid-cap biotechnology stock. The consensus leans bullish, with recent institutional ratings including 'Overweight' from JP Morgan, 'Buy' from B. Riley and HC Wainwright, and 'Neutral' from Goldman Sachs, indicating a generally positive but cautiously optimistic view. The average revenue estimate for the period is $2.04 billion, with a wide range from $1.90 billion to $2.14 billion, and the average EPS estimate is $3.92, ranging from $3.57 to $4.15, but a consensus price target is not provided in the data, preventing an upside/downside calculation. The wide range in both revenue and EPS estimates signals high uncertainty among analysts regarding the precise trajectory of BRIUMVI's commercial uptake and the company's future profitability. The high target of $4.15 for EPS likely assumes successful market penetration, market share gains, and potentially pipeline successes, while the low end of $3.57 may factor in competitive pressures or slower-than-expected adoption. The limited number of covering analysts and the absence of a published price target range imply that institutional interest, while present, is not yet broad, which can lead to higher stock price volatility and less efficient price discovery as the investment story continues to develop.
Bulls vs Bears: TGTX Investment Factors
The bull case, grounded in explosive 78% YoY revenue growth and a profitable turnaround, currently holds stronger evidence. The bear case is primarily a narrative of risk concentration and market skepticism, not fundamental failure. The single most important tension in the investment debate is whether BRIUMVI's current commercial momentum can be sustained long enough to overcome the stock's high volatility and single-asset risk, thereby re-rating the valuation from its depressed trailing PE of 9.62 towards a more typical growth biotech multiple. The resolution hinges on sequential quarterly revenue growth and margin stability.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue of $192.57 million grew 78% YoY and 19% sequentially, demonstrating accelerating commercial traction for BRIUMVI. This growth is the core driver of the investment thesis, indicating successful market penetration.
- The company reported Q4 2025 net income of $23.04 million, a dramatic turnaround from a net loss of -$107.07 million in Q1 2024. This validates the commercial model's scalability, with operating margins reaching 26.22%.
- Attractive Valuation on Earnings: With a trailing PE of 9.62, TGTX trades at a significant discount to typical biotech growth stocks. This low multiple, near the bottom of its own historical range, prices in substantial skepticism despite strong fundamentals.
- Strong Balance Sheet & Margins: A current ratio of 4.10 and debt-to-equity of 0.40 provide financial flexibility. Gross margins of 80.16% are robust, supporting future profitability as revenue scales.
Bearish
- Extreme Dependence on Single Asset: Approximately 98% of Q4 revenue ($189.11M of $192.57M) came from BRIUMVI product sales. The entire investment thesis is vulnerable to any competitive, clinical, or reimbursement setback for this one drug.
- High Volatility & Underperformance: A beta of 1.755 makes the stock ~75% more volatile than the market, explaining its severe -42.70% 1-year relative strength. This high volatility deters risk-averse investors and amplifies downside on negative news.
- Negative Free Cash Flow: Trailing twelve-month free cash flow is -$24.99 million, indicating the company is still burning cash to fund growth. This raises sustainability questions until operating cash flow turns consistently positive.
- Limited Analyst Coverage & High Uncertainty: Only 3 analysts provide estimates, and the EPS forecast range is wide ($3.57 to $4.15), reflecting high uncertainty about BRIUMVI's ultimate peak sales and competitive durability.
TGTX Technical Analysis
The stock is in a pronounced downtrend over the past year, evidenced by a -7.80% 1-year price change, which starkly contrasts with the S&P 500's 34.9% gain, resulting in a severe -42.70% relative strength. Currently trading at $35.33, the price sits at approximately 68% of its 52-week range ($25.28 to $46.48), indicating it is in the lower-mid portion of its annual band, which may suggest a potential value opportunity but also reflects persistent selling pressure and underperformance. Recent momentum, however, shows a significant short-term reversal, with the stock up 17.61% over the past month and 15.57% over the past three months, strongly outperforming the market's 7.36% and 2.67% gains, respectively, signaling a potential bullish inflection point after a prolonged decline. This short-term bullish momentum sharply diverges from the longer-term downtrend, suggesting a possible trend reversal or a significant relief rally, potentially driven by improved quarterly fundamentals or positive sentiment around BRIUMVI's launch trajectory. The stock's beta of 1.755 indicates it is approximately 75% more volatile than the broader market, which explains the magnitude of both its recent gains and its prior underperformance, making it a higher-risk, higher-potential-reward proposition for tactical traders. Key technical levels to watch are the 52-week low of $25.28, which represents critical support, and the 52-week high of $46.48, which serves as major resistance; a sustained breakout above the recent consolidation range could target the $46 area, while a breakdown below $25 would signal a resumption of the primary downtrend. The stock's high volatility, as quantified by its 1.755 beta, necessitates careful position sizing for risk management, as its price swings are significantly amplified compared to the overall market. The recent positive price action, coupled with a still-depressed position relative to its 52-week high, leaves room for further recovery if the fundamental story continues to improve, but the high beta means any negative news could trigger outsized declines.
Beta
1.68
1.68x market volatility
Max Drawdown
-42.0%
Largest decline past year
52-Week Range
$25-$42
Price range past year
Annual Return
+20.4%
Cumulative gain past year
| Period | TGTX Return | S&P 500 |
|---|---|---|
| 1m | +24.6% | +11.4% |
| 3m | +51.2% | +8.3% |
| 6m | +30.2% | +9.4% |
| 1y | +20.4% | +31.3% |
| ytd | +43.3% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TGTX Fundamental Analysis
Revenue growth is accelerating dramatically, with Q4 2025 revenue of $192.57 million representing a 78% year-over-year increase from $108.19 million in Q4 2024, driven by the commercial launch of BRIUMVI. This growth trajectory is robust on a sequential basis as well, with Q4 revenue up 19% from Q3's $161.71 million, indicating strong quarterly execution. Revenue segment data shows the vast majority, $189.11 million, comes from Product sales (presumably BRIUMVI), with smaller contributions from Royalty ($5.01 million) and Other Revenue ($3.03 million), confirming the launch is the primary growth engine and the investment thesis hinges on its continued success. The company has achieved profitability, reporting net income of $23.04 million for Q4 2025, a significant improvement from a net loss of -$107.07 million in Q1 2024, marking a successful transition to a profitable commercial entity. Gross margins are exceptionally strong at 80.16% for the quarter, consistent with the high-margin profile typical of successful biotechnology therapeutics, while operating margin was 26.22%, demonstrating the scalability of the commercial model as revenue scales. The path to profitability has been clear, with net income turning positive in recent quarters, supported by the rapid revenue expansion and controlled operating expenses. Balance sheet health is solid, with a strong current ratio of 4.10 and a manageable debt-to-equity ratio of 0.40, indicating ample liquidity and a conservative capital structure. However, free cash flow over the trailing twelve months remains negative at -$24.99 million, suggesting the company is still in an investment phase, funding growth initiatives internally from its cash balance rather than generating surplus cash. Return on equity is exceptionally high at 69.01%, though this metric can be inflated for companies with low equity bases; the key focus remains on converting the strong revenue growth into sustained positive operating and free cash flow to ensure long-term financial sustainability.
Quarterly Revenue
$192574000.0B
2025-12
Revenue YoY Growth
+0.78%
YoY Comparison
Gross Margin
+0.80%
Latest Quarter
Free Cash Flow
$-24986000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TGTX Overvalued?
Given the company's positive net income of $23.04 million in the latest quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 9.62, while the forward PE is 14.35, based on estimated EPS of $3.92; the higher forward multiple suggests the market is pricing in significant future earnings growth, anticipating a nearly 50% expansion in the earnings multiple as profitability scales. Compared to typical biotechnology industry averages, which often trade at elevated multiples due to growth expectations, TGTX's trailing PE of 9.62 appears to be at a substantial discount, though a direct industry average PE is not provided in the data. The stock's Price-to-Sales (PS) ratio of 6.98 and EV/Sales of 8.40 are more standard for a commercial-stage biotech with rapid growth, and the discount on the PE ratio likely reflects the market's caution regarding the sustainability of its newfound profitability and competitive dynamics in the MS market. Historically, the stock's own valuation has compressed significantly from extreme levels; for instance, its PE ratio was 46.25 at the end of Q4 2025 and has ranged wildly in prior periods. The current trailing PE of 9.62 is near the lower end of its recent historical spectrum, suggesting the market may be undervaluing its current profitable state relative to its own history, potentially due to the broader year-long stock price decline. This positioning near historical lows could indicate a value opportunity if the company can consistently execute and grow earnings, but it also reflects skepticism that needs to be overcome through continued strong quarterly results.
PE
9.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -50x~286x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on extreme product concentration, with ~98% of revenue from BRIUMVI, making the company a binary bet on one drug's success. While profitability has been achieved, negative TTM free cash flow of -$24.99 million indicates the business is not yet self-funding, relying on its balance sheet. The high return on equity of 69.01% is impressive but can be distorted by a low equity base and may not be sustainable as the capital structure normalizes.
Market & Competitive Risks are pronounced. The stock's beta of 1.755 signals it will experience amplified swings versus the broader market, which has contributed to its severe underperformance (-42.7% relative strength). Trading at a forward PE of 14.35, the market is pricing in growth, but any deceleration in BRIUMVI's launch trajectory could trigger multiple compression. The company operates in the fiercely competitive multiple sclerosis market against entrenched players with greater resources, posing a constant threat to market share gains and pricing power.
The Worst-Case Scenario involves BRIUMVI facing significant competitive or safety setbacks, leading to a rapid deceleration in quarterly revenue growth. Combined with the stock's high beta, this could trigger a swift decline towards its 52-week low of $25.28. From the current price of $35.33, this represents a realistic downside of approximately -28%. A breach of this support could see the stock test even lower levels, especially if negative free cash flow persists, eroding the strong current ratio of 4.10.
FAQ
The key risks, in order of severity, are: 1) Product Concentration: ~98% of revenue comes from BRIUMVI; any setback is catastrophic. 2) High Volatility: A beta of 1.755 means the stock is ~75% more volatile than the market, leading to painful drawdowns (1-year max drawdown of -42.01%). 3) Financial Sustainability: Despite profitability, TTM free cash flow remains negative at -$24.99M. 4) Competitive & Market Risks: Operating in the competitive MS market against larger players, with limited analyst coverage (only 3 analysts) increasing uncertainty and price dislocation risk.
The 12-month outlook presents three scenarios. The Base Case (50% probability) sees the stock trading between $35 and $40, assuming BRIUMVI meets consensus EPS estimates of $3.92 and growth moderates. The Bull Case (30% probability) targets $42 to $46, driven by sustained high growth and valuation re-rating. The Bear Case (20% probability) warns of a drop to $25-$30 if growth stalls. The Base Case is most likely, anchored by the company's current execution but tempered by the competitive landscape and high volatility. The key assumption is that sequential quarterly revenue growth remains positive.
Based on earnings, TGTX appears significantly undervalued. Its trailing PE of 9.62 is exceptionally low for a biotech company with 78% revenue growth and 26% operating margins. Historically, its own PE has been much higher (e.g., 46.25 at end of Q4 2025). The forward PE of 14.35 implies the market expects earnings growth, but still at a discount. The Price-to-Sales of 6.98 is more in line with growth biotechs. The market is pricing in substantial risk (single-asset dependence, competition), creating a discount that may be overdone if execution continues. The stock is undervalued on an absolute P/E basis but fairly valued when its unique risks are considered.
TGTX presents a compelling but high-risk opportunity for investors comfortable with volatility. The valuation is attractive with a trailing PE of 9.62, and fundamentals are strong with 78% YoY revenue growth and recent profitability. The primary appeal is the asymmetry between its depressed stock price and improving commercial execution. However, it is a binary bet on one drug (BRIUMVI) and carries a high beta of 1.755, meaning large price swings are likely. It is a good buy for aggressive growth investors seeking undervalued turnarounds, but unsuitable for conservative or income-focused portfolios.
TGTX is primarily suitable for a medium- to long-term investment horizon of 2-3 years. This allows time for the BRIUMVI launch story to fully play out, for pipeline assets to develop, and for the company to potentially generate consistent free cash flow. Its high beta (1.755) and lack of dividend make it a poor fit for short-term trading or income investors, as volatility can quickly erase gains. The investment thesis is based on fundamental execution over several quarters, not short-term technical moves. A minimum holding period of 12-18 months is suggested to weather volatility and assess the commercial trajectory.